PANDORA v2.0: Benchmarking peptide-MHC II models and software improvements

Front Immunol. 2023 Dec 8:14:1285899. doi: 10.3389/fimmu.2023.1285899. eCollection 2023.

Abstract

T-cell specificity to differentiate between self and non-self relies on T-cell receptor (TCR) recognition of peptides presented by the Major Histocompatibility Complex (MHC). Investigations into the three-dimensional (3D) structures of peptide:MHC (pMHC) complexes have provided valuable insights of MHC functions. Given the limited availability of experimental pMHC structures and considerable diversity of peptides and MHC alleles, it calls for the development of efficient and reliable computational approaches for modeling pMHC structures. Here we present an update of PANDORA and the systematic evaluation of its performance in modelling 3D structures of pMHC class II complexes (pMHC-II), which play a key role in the cancer immune response. PANDORA is a modelling software that can build low-energy models in a few minutes by restraining peptide residues inside the MHC-II binding groove. We benchmarked PANDORA on 136 experimentally determined pMHC-II structures covering 44 unique αβ chain pairs. Our pipeline achieves a median backbone Ligand-Root Mean Squared Deviation (L-RMSD) of 0.42 Å on the binding core and 0.88 Å on the whole peptide for the benchmark dataset. We incorporated software improvements to make PANDORA a pan-allele framework and improved the user interface and software quality. Its computational efficiency allows enriching the wealth of pMHC binding affinity and mass spectrometry data with 3D models. These models can be used as a starting point for molecular dynamics simulations or structure-boosted deep learning algorithms to identify MHC-binding peptides. PANDORA is available as a Python package through Conda or as a source installation at https://github.com/X-lab-3D/PANDORA.

Keywords: 3D structures; MHC class II; large-scale 3D modelling; peptide binding; peptide:MHC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benchmarking*
  • Histocompatibility Antigens
  • Major Histocompatibility Complex
  • Peptides* / metabolism
  • Software

Substances

  • Peptides
  • Histocompatibility Antigens

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. LX, FP, and DM received support from the Hypatia Fellowship from Radboudumc (Rv819.52706). GR is supported by Europees Fonds voor Regionale Ontwikkeling (EFRO) (R0005582).